CIK 0001695357
PRVB Provention Bio, Inc.
Insider trading from SEC Form 4. Last filing Apr 28, 2023.
In brief
Provention Bio, Inc. (PRVB) has 51 SEC Form 4 filings on file from 15 insiders, the latest filed on Apr 28, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
10 open-market trades have been scored at PRVB. The newest: Sessa Capital (Master), L.P. (10% owner) sold $53M of stock on Apr 14, 2023, filed Apr 18, 2023, scored 42 (moderate). 3 insiders sold within 14 days of each other around Feb 10, 2023.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Signals
Open-market buys and sells at Provention Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Sessa Capital (Master), L.P. owner sell | $53M 2,190,549 shares | -12% | - | |
| 36Weak | Jason Hoitt Chief Commercial Officer sell | $45k 4,500 shares | -100% | - | |
| 17Weak | Francisco Leon Chief Scientific Officer sell | $767k 75,985 shares | -5% | - | |
| 27Weak | Ashleigh Palmer Director and CEO sell | $765k 75,835 shares | -3% | - | |
| 8Weak | Francisco Leon Chief Scientific Officer sell | $247k 24,015 shares | -2% | - | |
| 18Weak | Ashleigh Palmer Director and CEO sell | $248k 24,165 shares | -1% | - | |
| 57Moderate | Sessa Capital (Master), L.P. owner sell | $28M 3,000,000 shares | -20% | - | |
| 30Weak | Francisco Leon Chief Scientific Officer sell | $1.9M 187,000 shares | -11% | - | |
| 10Weak | Francisco Leon Chief Scientific Officer sell | $107k 10,674 shares | -1% | - | |
| 0Weak | Francisco Leon Chief Scientific Officer sell | $19k 1,943 shares | -0% | - |
Transactions
The newest 50 of 138 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 27, 2023 | Sessa Capital (Master), L.P. owner | UTender of shares Common Stock | -15,567,497 | - | - | 0 | Apr 28, 2023 |
| Apr 27, 2023 | Nancy Wysenski director | DDisposition to issuer Option to Purchase Common Stockderivative | -128,981 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Thierry Chauche Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -375,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Wayne Pisano director | UTender of shares Common Stock | -7,500 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Rita Jain director | DDisposition to issuer Option to Purchase Common Stockderivative | -66,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Avery W Catlin director | UTender of shares Common Stockindirect: By the Avery W. Catlin Revocable Trust | -10,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | John Kenneth Jenkins director | DDisposition to issuer Option to Purchase Common Stockderivative | -128,981 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Ashleigh Palmer Director and CEO | UTender of shares Common Stock | -2,570,050 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Miyoko Christina Yi Chief Operations Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -300,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Francisco Leon Chief Scientific Officer | UTender of shares Common Stock | -73,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Heidy King-Jones Chief Legal Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -300,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Benedict Osorio Chief Quality Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -100,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Justin Vogel Chief Accounting Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -88,185 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Eleanor Ramos Chief Medical Officer | UTender of shares Common Stock | -70,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Jason Hoitt Chief Commercial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -400,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Benedict Osorio Chief Quality Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -70,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | John Kenneth Jenkins director | DDisposition to issuer Option to Purchase Common Stockderivative | -23,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Avery W Catlin director | UTender of shares Common Stockindirect: By the Avery Catlin Charitable Giving Fund | -10,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Francisco Leon Chief Scientific Officer | UTender of shares Common Stockindirect: By Immunosoma LLC | -1,500,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Heidy King-Jones Chief Legal Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -139,500 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Thierry Chauche Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -50,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Wayne Pisano director | DDisposition to issuer Option to Purchase Common Stockderivative | -128,981 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Justin Vogel Chief Accounting Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -45,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Ashleigh Palmer Director and CEO | DDisposition to issuer Option to Purchase Common Stockderivative | -441,720 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Nancy Wysenski director | DDisposition to issuer Option to Purchase Common Stockderivative | -22,200 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Eleanor Ramos Chief Medical Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -460,462 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Miyoko Christina Yi Chief Operations Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -50,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Jason Hoitt Chief Commercial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -137,750 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Benedict Osorio Chief Quality Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -80,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | John Kenneth Jenkins director | DDisposition to issuer Option to Purchase Common Stockderivative | -33,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Ashleigh Palmer Director and CEO | DDisposition to issuer Option to Purchase Common Stockderivative | -400,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Thierry Chauche Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -200,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Heidy King-Jones Chief Legal Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -145,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Miyoko Christina Yi Chief Operations Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -187,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Wayne Pisano director | DDisposition to issuer Option to Purchase Common Stockderivative | -24,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Eleanor Ramos Chief Medical Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -400,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Nancy Wysenski director | DDisposition to issuer Option to Purchase Common Stockderivative | -23,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Francisco Leon Chief Scientific Officer | UTender of shares Common Stockindirect: By Trust | -1,000,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Jason Hoitt Chief Commercial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -139,500 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Justin Vogel Chief Accounting Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -60,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Avery W Catlin director | DDisposition to issuer Option to Purchase Common Stockderivative | -128,981 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Avery W Catlin director | DDisposition to issuer Option to Purchase Common Stockderivative | -24,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Benedict Osorio Chief Quality Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -187,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Ashleigh Palmer Director and CEO | DDisposition to issuer Option to Purchase Common Stockderivative | -137,750 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Heidy King-Jones Chief Legal Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -200,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Wayne Pisano director | DDisposition to issuer Option to Purchase Common Stockderivative | -22,200 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Justin Vogel Chief Accounting Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -66,000 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Eleanor Ramos Chief Medical Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -137,750 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Francisco Leon Chief Scientific Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -242,103 | - | - | 0 | Apr 27, 2023 |
| Apr 27, 2023 | Jason Hoitt Chief Commercial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -145,000 | - | - | 0 | Apr 27, 2023 |
50 of 138 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Avery W Catlindirector
- Thierry ChaucheChief Financial Officer
- Jason HoittChief Commercial Officer
- Rita Jaindirector, officer
- John Kenneth Jenkinsdirector
- Heidy King-JonesChief Legal Officer
- Francisco LeonChief Scientific Officer
- Benedict OsorioChief Quality Officer
- Ashleigh PalmerDirector and CEO
- Wayne Pisanodirector
- Eleanor RamosChief Medical Officer
- Sessa Capital (Master), L.P.director, owner
- Justin VogelChief Accounting Officer
- Nancy Wysenskidirector
- Miyoko Christina YiChief Operations Officer
Questions about PRVB
Answered from the filings on this page, as of the latest one.
Are insiders buying PRVB?
No. In the last 90 days no insider at Provention Bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade PRVB on the open market?
Sessa Capital (Master), L.P. (10% owner) sold $53M of PRVB on Apr 14, 2023 and filed the Form 4 on Apr 18, 2023. InsiderTell scored 42 (moderate).
How many insiders file Form 4 at Provention Bio, Inc.?
15 people have filed a Form 4 at Provention Bio, Inc., among them Avery W Catlin (director), Thierry Chauche (Chief Financial Officer), Jason Hoitt (Chief Commercial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.